Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy

Journal of Clinical Oncology

Volumn 35, Issue 13, 2017, Pages 1387-1394

  Wang, Kyle ^a   Eblan, Michael J ^a   Deal, Allison M ^a   Lipner, Matthew ^a   Zagar, Timothy M ^a   Wang, Yue ^a   Mavroidis, Panayiotis ^a   Lee, Carrie B ^a   Jensen, Brian C ^a   Rosenman, Julian G ^a   Socinski, Mark A ^c   Stinchcombe, Thomas E ^b   Marks, Lawrence B ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b DUKE UNIVERSITY   (United States)

^c FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; VINORELBINE TARTRATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; INTERNATIONAL SOCIETY OF HYPERTENSION SCORE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERICARDITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; UNSTABLE ANGINA PECTORIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CHILD; CLINICAL TRIAL; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RADIATION INJURIES; RADIATION RESPONSE;

ADOLESCENT; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOTOXICITY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY;

EID: 85018357228     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.0229     Document Type: Article

References (46)

1. Cuzick J, Stewart H, Rutqvist L, et al: Causespecific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
2. Darby SC, McGale P, Taylor CW, et al: Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557-565, 2005
3. Hooning MJ, Botma A, Aleman BM, et al: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99: 365-375, 2007
4. van Nimwegen FA, Schaapveld M, Janus CP, et al: Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007-1017, 2015
5. van Nimwegen FA, Schaapveld M, Cutter DJ, et al: Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34:235-243, 2016
6. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993
7. Darby SC, Cutter DJ, Boerma M, et al: Radiation-related heart disease: Current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76: 656-665, 2010
8. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013
9. Gagliardi G, Constine LS, Moiseenko V, et al: Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:S77-S85, 2010
10. Dautzenberg B, Arriagada R, Chammard AB, et al: A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 86: 265-273, 1999
11. Lally BE, Detterbeck FC, Geiger AM, et al: The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer 110: 911-917, 2007
12. Douillard JY, Rosell R, De Lena M, et al: Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 72:695-701, 2008
13. Schytte T, Hansen O, Stolberg-Rohr T, et al: Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol 49:1058-1060, 2010
14. Hardy D, Liu CC, Cormier JN, et al: Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 21:1825-1833, 2010
15. Bradley JD, Paulus R, Komaki R, et al: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187-199, 2015
16. Socinski MA, Rosenman JG, Halle J, et al: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified phase I/II trial. Cancer 92: 1213-1223, 2001
17. Marks LB, Garst J, Socinski MA, et al: Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 22:4329-4340, 2004
18. Socinski MA, Morris DE, Halle JS, et al: Induction and concurrent chemotherapy with highdose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22: 4341-4350, 2004
19. Socinski MA, Blackstock AW, Bogart JA, et al: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and doseescalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457-2463, 2008
20. Stinchcombe TE, Morris DE, Lee CB, et al: Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy)with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 3:250-257, 2008
21. Lee CB, Stinchcombe TE, Moore DT, et al: Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:74-79, 2009
22. Socinski MA, Stinchcombe TE, Moore DT, et al: Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-smallcell lung cancer: Results of a phase I/II trial. J Clin Oncol 30:3953-3959, 2012
23. Tewell MA, Adams R: The PLUNC 3D treatment planning system: A dynamic alternative to commercially available systems. Med Dosim 29: 134-138, 2004
24. Feng M, Moran JM, Koelling T, et al: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10-18, 2011
25. Mendis S, Lindholm LH, Mancia G, et al: World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: Assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middleincome countries. J Hypertens 25:1578-1582, 2007
26. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
27. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007
28. Radiation Therapy Oncology Group (RTOG) Foundation: RTOG 1306 Protocol Information: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC). Version date May 16, 2016. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1306
29. Radiation Therapy Oncology Group (RTOG) Foundation: RTOG 1308 Protocol Information: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC. Version date October 5, 2015. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1308
30. Allan E, Williams TM, Grecula JC, et al: Mortality, cardiac toxicity, and radiation dose to the heart in patients treated with curative intent fractionated radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 93:3, 2015 (suppl; abstr 1012)
31. Tucker SL, Liu A, Gomez D, et al: Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 119:495-500, 2016
32. Lauk S, Kiszel Z, Buschmann J, et al: Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys 11:801-808, 1985
33. Schultz-Hector S, Sund M, Thames HD: Fractionation response and repair kinetics of radiationinduced heart failure in the rat. Radiother Oncol 23: 33-40, 1992
34. Marks LB, Yu X, Prosnitz RG, et al: The incidence and functional consequences of RTassociated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63:214-223, 2005
35. Gyenes G, Fornander T, Carlens P, et al: Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 28:1235-1241, 1994
36. Gyenes G, Fornander T, Carlens P, et al: Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: A prospective study. Int J Radiat Oncol Biol Phys 36:899-905, 1996
37. Seddon B, Cook A, Gothard L, et al: Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol 64:53-63, 2002
38. Hatakenaka M, Yonezawa M, Nonoshita T, et al: Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: Magnetic resonance evaluation. Int J Radiat Oncol Biol Phys 83:e67-e73, 2012
39. Wei X, Liu HH, Tucker SL, et al: Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70:707-714, 2008
40. Dropcho EJ: Neurotoxicity of radiation therapy. Neurol Clin 28:217-234, 2010
41. Maraldo MV, Giusti F, Vogelius IR, et al: Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2:e492-e502, 2015
42. Chun SG, Hu C, Choy H, et al: Comparison of 3-D conformal and intensity modulated radiation therapy outcomes for locally advanced non-small cell lung cancer in NRG Oncology/RTOG 0617. Int J Radiat Oncol Biol Phys 93:3s, 2015 (suppl; abstr 2)
43. Movsas B, Hu C, Sloan J, et al: Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: A secondary analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol 2: 359-367, 2016
44. Giaddui T, Chen W, Yu J, et al: Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: Phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol 11:66, 2016
45. Braunholtz DA, Edwards SJ, Lilford RJ: Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 54:217-224, 2001
46. Nolan MT, Lowenthal RM, Venn A, et al: Chemotherapy-related cardiomyopathy: A neglected aspect of cancer survivorship. Intern Med J 44: 939-950, 2014